# OnCo record nct06634589 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06634589/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06634589", "NCT06634589" ;
  schema:name "A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies"@en ;
  schema:description "A phase 1/2 trial of Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab and Obinutuzumab in non-Hodgkin lymphoma, run by BeOne Medicines, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06634589/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06634589> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-11-27" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:companies <https://onco.cc/companies/beone/> .